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AbstrAct
Introduction Semantic dementia, including the 
semantic variant of primary progressive aphasia (svPPA), 
is strongly associated with TAR-DNA binding protein 43 
(TDP-43) type C pathology. It provides a useful model 
in which to test the specificity of in vivo binding of the 
putative tau ligand [18F]AV-1451, which is elevated in 
frontotemporal lobar degeneration tauopathies.
Methods and results Seven patients (five with svPPA 
and two with ’right’ semantic dementia) and 12 healthy 
controls underwent positron emission tomography 
brain imaging with [18F]AV-1451. Two independent 
preprocessing methods were used. For both methods, 
all patients had clearly elevated binding potential 
(BPND (non-displaceable binding potential)) in temporal 
lobes, lateralising according to their clinical syndrome 
and evident in raw images. Region of interest analyses 
confirmed that BPND was significantly increased in 
temporal regions, insula and fusiform gyrus, consistent 
with those areas known to be most affected in semantic 
dementia. Hierarchical cluster analysis, based on the 
distribution of [18F]AV-1451 binding potential, separated 
semantic dementia from controls with 86% sensitivity 
and 100% specificity.
conclusions [18F]AV-1451 binds in vivo regions that 
are likely to contain TDP-43 and not significant tau 
pathology. While this suggests a non-tau target for [18F]
AV-1451, the pathological regions in semantic dementia 
do not normally contain significant levels of recently 
proposed ’off target’ binding sites for [18F]AV-1451, 
such as neuronal monoamine oxidase or neuromelanin. 
Postmortem and longitudinal data will be useful to 
assess the utility of [18F]AV-1451 to differentiate 
and track different types of frontotemporal lobar 
degeneration.
IntroductIon
The importance of biomarkers in neurodegenera-
tive disorders is well established. Positron emission 
tomography (PET) has played an important role in 
biomarker development, illustrated by the impact 
of the Pittsburgh compound B on both research 
and clinical practice in Alzheimer’s disease.1 While 
beta-amyloid is central to the neuropathology of 
Alzheimer’s disease, in the vast majority of cases of 
frontotemporal lobar degeneration, the pathology 
is characterised by misfolding and aggregation of 
either tau (~40%) or TDP-43 (~50%), with fewer 
cases of fused in sarcoma pathology (<10%).2–4 A 
major aim for clinical research and drug develop-
ment has been the development of biomarkers that 
enable pathological classification and longitudinal 
assessment in vivo, with quantitative and qualitative 
differentiation of neurodegenerative syndromes 
based on their underlying proteinopathy: tau versus 
TDP-43 versus beta-amyloid.
The radioligand [18F]AV-1451 was developed 
from compound screening in Alzheimer’s brains 
and is selective for tau versus beta-amyloid and 
versus alpha-synuclein.5 In vitro and in vivo 
studies have confirmed that [18F]AV-1451 binding 
in Alzheimer’s disease correlates strongly with 
phenotypical variation,6 clinical severity and Braak 
stage.7–9 There are fewer studies in frontotemporal 
lobar degeneration, but [18F]AV-1451 has also been 
shown to be sensitive in vivo to frontotemporal 
dementia associated with mutation of the microtu-
bule-associated protein tau (MAPT) gene10–12 and 
in progressive supranuclear palsy.13 There is also 
evidence of modest binding to primary tauopa-
thies in postmortem studies.14 However, the spec-
ificity of [18F]AV-1451 for tau pathology remains 
controversial.
Here, we test the properties of [18F]AV-1451 in 
semantic dementia, including the semantic variant 
of primary progressive aphasia (svPPA) and its 
non-dominant homologue, right semantic dementia 
(R-SD). Both syndromes display TDP-43 pathology 
in 75%–90% of cases,15 16 with tau pathology rarely 
present at postmortem. We test two complementary 
hypotheses:
1. In clinically diagnosed semantic dementia 
(likely TDP-43 pathology), the non-displaceable 
binding potential (BPND) of [
18F]AV-1451 is not 
increased compared with healthy older adults.
2. Independent of absolute levels of [18F]AV-
1451 BPND, the distribution of binding across 
brain regions is similar in patients and healthy 
controls.
Methods
This study formed part of the Neuroimaging of 
Inflammation in Memory and Related Other Disor-
ders study.17 The study protocol was approved 
by the UK National Research Ethics Service, East 
of England, Cambridge Central Research Ethics 
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Committee (reference: 13/EE/0104) and the Administration of 
Radioactive Substances Advisory Committee. Five participants 
with svPPA and two with R-SD were recruited from the specialist 
clinic for frontotemporal dementia at the Cambridge University 
Hospitals National Health Service Foundation Trust. Participants 
were diagnosed according to published consensus criteria.18 Four 
of the seven participants had available biomarkers for Alzhei-
mer’s pathology. Case L5 had a negative Pittsburgh compound B 
PET, whereas cases R3, L6 and L7 had cerebrospinal fluid 
beta-amyloid, total tau and ratio levels not supportive of Alzhei-
mer’s disease. Clinical vignettes and neuropsychological test 
scores are summarised in table 1. Twelve similarly aged healthy 
participants acted as controls.
MrI and Pet imaging
Each participant underwent T1-weighted MRI (3T Siemens 
Trio or 3T Siemens Prisma, MPRAGE sequence, 1 mm isotropic 
voxels) before PET. Manufacture of [18F]AV-1451 used 
synthetic methods developed by Avid Radiopharmaceuticals, 
modified for GE TracerLab FX-FN synthesizer at the Wolfson 
Brain Imaging Centre, Cambridge. A GE Discovery 690 PET/
CT scanner was used. A total of 370 MBq of [18F]AV-1451 
was injected over 30 s at the onset of a 90 min scan. Emission 
data were reconstructed in 58 contiguous time frame images. 
Each emission frame was reconstructed using the PROMIS 3D 
filtered back projection algorithm into a 128×128 matrix 30 cm 
transaxial field of view, with a transaxial Hann filter cut-off at 
the Nyquist frequency.19 Corrections were applied for randoms, 
dead time, normalisation, scatter, attenuation and sensitivity. 
Each emission image series was aligned to correct for patient 
motion during data acquisition (www. fil. ion. ucl. ac. uk/ spm/ soft-
ware/ spm8). The BPND was determined by kinetic modelling 
with a simplified reference tissue model. The reference tissue 
was defined in the superior grey matter of the cerebellum, using 
a 90% grey matter threshold on the grey matter probability map 
produced by SPM8, smoothed to the PET resolution. The supe-
rior cerebellum was chosen as a reference region as it is unlikely 
to contain substantial pathology in semantic dementia (0 out of 
15 cases of semantic dementia in the Cambridge Brain Bank had 
cerebellar pathology).
table 1 Demographic, clinical, neuropsychological (ACE-R, FAB and PPT) and diagnosis for each participant with semantic dementia and for the 
group of 12 controls
case number demographics
symptom 
duration Presenting clinical features Ace-r FAb PPt diagnosis
L1 71, male, left-handed, 
15 years of education
8 years Anomia
Impaired single-word comprehension
Surface dyslexia
Obsessional behaviour
43 11 25 svPPA
L2 69, male, right-handed, 
9 years of education
7 years Anomia
Impaired single-word comprehension
Surface dyslexia
Inability to use previously familiar tools
9 3 0 svPPA
R3 59, male, right-handed, 
14 years of education
6 years Rigid obsessional behaviour
Reduced empathy
Prosopagnosia
Anomia
Impaired single-word comprehension
Surface dyslexia
79 15 48 R-SD
R4 68, male, right-handed, 
16 years of education
5 years Rigid obsessional behaviour
Reduced empathy
Prosopagnosia
Anomia
Impaired single-word comprehension
Surface dyslexia
77 11 28 R-SD
L5 64, female, right-handed, 
14 years of education
4 years Anomia
Impaired single-word comprehension
Surface dyslexia
Prosopagnosia
Concrete thinking
72 16 44 svPPA
L6 66, male, left-handed, 
17 years of education
4 years Anomia
Impaired single-word comprehension
Surface dyslexia
Withdrawn behaviour
Prosopagnosia
71 18 48 svPPA
L7 64, male, right-handed, 
13 years of education
6 years Anomia
Impaired single-word comprehension
Surface dyslexia
Mild prosopagnosia
68 15 47 svPPA
Twelve controls Age: 65.5 (range 55–74, 
SD 7.1)
Sex: 6:6
Education years: 15.8 
(range 11–19, SD 2.1)
NA NA 95.3 (range 
89–99, SD 
3.2)
– – –
ACE-R, Addenbrooke’s Cognitive Examination—Revised; FAB, Frontal Assessment Battery; PPT, Pyramids and Palm Trees; R-SD, right semantic dementia; svPPA, semantic variant 
of primary progressive aphasia.
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Two independent preprocessing methods were evaluated. 
(1) The data were coregistered with T1-weighted images. 
Regions of interest were defined by cortical parcellation and 
modified subcortical segmentation using the Desikan-Kil-
liany atlas in the PetSurfer toolbox within Freesurfer.20 21 
The BPND values in each region were partial volume corrected 
using the symmetric geometric transfer matrix method.22 (2) 
The mean aligned PET image, and hence the corresponding 
aligned dynamic PET image series, was rigidly registered to 
the T1-weighted image using SPM8, so as to extract values 
from the Hammersmith atlas n30r83 (http:// brain- develop-
ment. org/ brain- atlases) modified with brainstem and cere-
bellar parcellation. All region of interest data, including 
the reference tissue values, were corrected for the cerebro-
spinal fluid fraction through division with the mean region 
of interest probability (normalised to 1) of grey plus white 
matter segments, each smoothed to PET resolution.
Analysis
To test hypothesis 1, we used general linear models with t-tests 
for each region of interest, excluding extraparenchymal regions, 
first comparing each patient to the control group, as a case series 
(cf Bevan Jones et al10). We then compared the patients group-
wise to the controls. Data were corrected for multiple compar-
isons to control the false discovery rate (FDR) at q<0.05.23 24
To test hypothesis 2, regional binding potentials for each 
subject were converted to a linear vector. Spearman’s rank order 
method was used to perform non-parametric correlation with 
all other subjects, creating a correlation ‘similarity’ matrix of 
the distribution of BPND, disregarding its absolute intensity. The 
inverse of this matrix (the ‘dissimilarity’ matrix) formed the 
input to multidimensional scaling and hierarchical cluster anal-
ysis. The performance of both farthest neighbour and average 
linkage methods was assessed (cf Passamonti et al13).
results
Figure 1 shows the axial and sagittal views of the T1-weighted 
images for each participant with semantic dementia, confirming 
the severe asymmetric temporal polar atrophy in svPPA and 
R-SD, respectively. Also shown are the uncorrected raw [18F]
AV-1451 BPND maps for each individual patient and a repre-
sentative control. Statistical comparisons against controls using 
method 1 are shown for each patient individually and for the 
group. All patients had significant elevation of BPND in temporal 
lobes compared with controls, and in all but one individual, this 
survived correction for multiple comparisons across the whole 
brain. As a group, for method 1, significant elevation of BPND at 
false discovery rate (FDR q<0.05 was observed in the following 
regions of the left hemisphere: superior, middle and inferior 
temporal lobes; insula cortex; fusiform gyrus; temporal banks 
and accumbens. In the right hemisphere: amygdala, caudate and 
superior temporal cortex. For method 2, the following regions 
showed significant elevation of BPND at FDR q<0.05. In the 
left hemisphere: medial anterior and lateral anterior temporal 
lobes; superior, middle and inferior temporal gyri; fusiform 
gyrus; insula; thalamus and nucleus accumbens. In the right 
hemisphere: lateral anterior temporal lobe; middle and inferior 
temporal gyri and medial anterior temporal lobe.
Non-parametric multidimensional scaling of BPND distribution 
clearly separated patients from controls (figure 2). With either 
preprocessing method, hierarchical cluster analysis of these data 
detected SD with 86% sensitivity and 100% specificity. Cluster 
analysis, blinded by non-parametric methods to the degree of 
ligand binding, therefore provided statistically significant unsu-
pervised classification (Yates’ corrected χ2(1, n=19)=11.3, 
p=0.0008). Identical results were obtained with both average 
and farthest neighbour linkage methods. The patient misclassi-
fied as a control had mild and relatively early disease and lay 
between the control and patient distributions on multidimen-
sional scaling (figure 2, case L7).
dIscussIon
We present evidence for consistently elevated [18F]AV-1451 BPND 
in seven cases with either svPPA or its non-dominant right hemi-
sphere homologue, R-SD. Contrary to the null hypotheses, in 
all seven cases individually and at the group level, the regions 
known to be most affected by TDP-43 pathology25 26 demon-
strated increased [18F]AV-1451 binding compared with controls. 
This did not merely reflect a global increase in BPND, as six of 
the seven cases were correctly classified by the relative distribu-
tion of BPND across the brain. The significant regional binding 
to likely TDP-43 pathology in svPPA and R-SD indicates that 
this ligand is not selective for tau and casts doubt on the utility 
of [18F]AV-1451 to subtype frontotemporal dementias according 
to tau versus TDP-43 pathology. While this suggests that the use 
of [18F]AV-1451 to select tau-mediated frontotemporal dementia 
populations for clinical trials is unlikely to be effective, the ligand 
may still retain a potential role in the longitudinal assessment of 
the degree and distribution of pathological burden across the 
frontotemporal dementia spectrum.
Semantic dementia in the form of svPPA represents a highly 
stereotyped and well-defined clinical syndrome with character-
istic structural neuroimaging.27–29 Its non-dominant homologue 
displays similar features but typically with a later presentation, 
more behavioural disturbance and prosopagnosia.30 Within the 
spectrum of frontotemporal dementias, both svPPA and R-SD 
show very strong clinicopathological correlations with TDP-43 
pathology, especially type C.4 15 25 26 31 This contrasts with the 
behavioural variant of frontotemporal dementia which can 
result from either TDP-43 or tau pathology with approximately 
equal likelihood.
Although the majority of semantic dementia cases have 
TDP-43 pathology, a small minority of cases may arise from 
tauopathies, most often Alzheimer’s disease pathology or Pick’s 
disease pathology.15 16 31 In keeping with this, 25 of 34 patients 
clinically diagnosed with semantic dementia (or svPPA) and in 
the Cambridge Brain Bank are positive for ubiquitin or TDP-43 
and negative for both tau and beta-amyloid. Similarly, the recent 
report of postmortem examination in clinical cases of svPPA at 
four centres in North America16 confirmed that the majority 
(24/29) had TDP-43 pathology (mainly type C). The five who 
did not have TDP-43 pathology exhibited clinical features out 
of keeping with the classical syndrome of svPPA, such as short 
disease duration and extrapyramidal features. These features are 
not present in any of the individuals we report. Although we do 
not have autopsy confirmation of the cases reported here, four 
out of seven participants have negative biomarkers for Alzhei-
mer’s pathology and, overall, it is highly unlikely that the expla-
nation for our findings is that all individuals in our study had a 
primary or secondary tauopathy.
While the in vivo and postmortem studies of [18F]AV-1451 in 
Alzheimer’s disease are compelling, the binding characteristics 
of [18F]AV-1451 in non-AD tauopathies remain controversial. 
In vivo studies have been encouraging, with significant binding 
demonstrated in frontotemporal dementia due to mutations in 
the MAPT) gene10 12 32 and in progressive supranuclear palsy.13 
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This contrasts with reports from postmortem studies, which 
predominantly describe low level binding to the tau aggregates 
of frontotemporal lobar degeneration.14 33 34 These postmortem 
studies make it increasingly clear that the primary, tertiary and 
quaternary structures of tau, as well as the type and maturity 
of tau pathology,34 are important determinants of [18F]AV-1451 
binding. This implies that the predominantly straight filaments of 
4-repeat tau that constitute the pathology of progressive supra-
nuclear palsy and corticobasal degeneration, and the 3-repeat 
tau of intraneuronal Pick bodies, lead to less intense binding 
than that seen in Alzheimer’s pathology, with its balanced 3-/4-
repeat tauopathy in the form of paired helical filaments.
The discordance between in vivo and postmortem findings led 
to the proposal of ‘off target’ binding sites. In the last 2 years, 
several possibilities have been hypothesised, particularly to 
explain the characteristic pattern of basal ganglia binding seen 
in almost all participants. These include neuromelanin,33 35 iron, 
calcium and Biondi ring tangles.34 None of these potential targets 
is anatomically compatible with the pattern of cortical binding 
seen here, which is in a distribution expected for pathology 
in semantic dementia.25 31 One plausible explanation for the 
elevated signal observed here could be spill out from increased 
binding in white matter, for example, to the expression of mono-
amine oxidase B by reactive astrocytes. The intrinsic resolution 
Figure 1 Using data preprocessed by method 1. (Upper panel) Column 1: axial and sagittal views of T1-weighted images for each semantic dementia 
participant, column 2: raw axial and sagittal BPND maps for each patient, column 3: unthresholded surface-rendered regional T-maps for each subject against 
all controls and column 4: equivalent T-maps thresholded at q<0.05, corrected for false discovery rate. (Lower panel) T1-weighted images and BPND maps 
for a representative control and the group comparisons of all 7 patients versus 12 controls both uncorrected (column 3) and corrected for false discovery 
rate q<0.05 (column 4). The numbering of individual patients is consistent with figure 2 and table 1. BPND, non-displaceable binding potential. FDR, false 
discovery rate.
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of PET, combined with the degree of atrophy in the semantic 
dementia cohort, makes it very difficult to distinguish binding 
in white or grey matter. However, there is a paucity of evidence 
for [18F]AV-1451 binding to monoamine oxidase B, unlike other 
tau radioligands such as the THK compounds. The possibility 
of binding to monoamine oxidase B was explored early in the 
development of [18F]AV-1451,5 36 and its favourable profile in 
this regard was important in its progress to clinical studies.
Another possibility is that [18F]AV-1451 binds to very low 
levels of abnormal tau that have been reported to coexist with 
TDP-43 in some cases,25 to proteins associated with cellular 
stress in TDP-43 pathologies or to some other cellular marker 
of neurodegeneration. Alternatively, it could be that the in vivo 
binding demonstrated here mirrors the postmortem binding of 
[18F]AV-1451 to TDP-43 type C,14 34 despite the low level or 
absent binding to most TDP-43 pathology.14 34 Overall, we retain 
an open mind as to the identity of the non-Tau proteins and cell 
types to which [18F]AV-1451 is binding in semantic dementia.
One must also consider some caveats in the analytical methods 
of the imaging pipelines. In particular, the extreme regional 
atrophy of semantic dementia complicates normalisation and 
PET analysis, including modelling decisions such as partial 
volume correction, which is necessary in order to prevent signif-
icant binding being obscured by the degree of atrophy. Misreg-
istration errors arising from extreme atrophy may also influence 
PET estimates. However, these considerations are unlikely 
to account for our findings for two main reasons. First, the 
bright signal of elevated [18F]AV-1451 binding is visible in the 
temporal lobes of uncorrected BPND maps in all single subjects 
in native space (figure 1). Second, highly similar patterns of 
significant binding are seen with two independent methods 
of data preprocessing, using different tissue segmentation and 
correction methods and parcellation with different brain atlases. 
The use of an appropriate reference tissue region may also be 
complicated in neurodegenerative diseases. In particular, there 
is emerging evidence that specific patterns of atrophy occur in 
the cerebellum across a range of disorders.37 In frontotemporal 
dementia, cerebellar atrophy and pathology are well described in 
cases of the behavioural variant and particularly in cases resulting 
from expansions in C9orf72.38 However, in semantic dementia, 
cerebellar atrophy has not been described, and the typical distri-
bution of TDP-43 type C pathology does not involve the cere-
bellum.39 We have examined 15 cases of semantic dementia in the 
Cambridge Brain Bank, and in no case was cerebellar pathology 
found. Additional reassurance that our results are not driven by 
a possible group difference in cerebellar pathology comes from 
our hierarchical cluster analysis. This non-parametric analysis 
of the distribution of pathology across the whole brain is blind 
to absolute BPND values; the effect of a group difference in a 
reference region would be to change the overall level of binding 
across the brain, without modifying the relative distribution of 
pathology. The fact that we were able to recover the group struc-
ture with 86% sensitivity and 100% specificity argues against 
cerebellar pathology being a significant driver of our findings.
Validation of the specificity of [18F]AV-1451 binding in both 
Alzheimer’s disease and frontotemporal lobar degeneration is 
highly important. Binding in the presence of neurodegenera-
tion without tauopathy poses serious questions for both clinical 
and research applications of this ligand, although it may none-
theless be useful to evaluate the progression of neurodegener-
ative diseases and normal ageing. The magnitude of elevations 
in binding potential was similar to those previously observed in 
MAPT mutation10 and progressive supranuclear palsy, but lower 
than those observed in Alzheimer’s disease.13 While this study 
did not directly compare FTD-TDP (in semantic dementia) to 
FTD-tau cases, the lack of selectivity of [18F]AV-1451 for tauop-
athies challenges the utility of this ligand for pathological differ-
entiation in vivo. Determining the binding site or sites will be 
important as, even if this is not specific to tau aggregation, it 
may provide valuable insights into the cellular mechanisms of 
neurodegeneration, perhaps in regions that are yet to display 
volume loss or hypometabolism. In order to determine the best 
use of this ligand, full characterisation of the behaviour of [18F]
AV-1451 in frontotemporal lobar degeneration with longitu-
dinal imaging and postmortem validation is essential.
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